TISIDB

Summary
Symbol	SUPT16H
Name	SPT16 homolog, facilitates chromatin remodeling subunit
Aliases	FACTP140; SPT16/CDC68; FLJ14010; FLJ10857; CDC68; facilitates chromatin remodeling 140 kDa subunit; suppress ......
Chromosomal Location	14q11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Chromosome Note=Colocalizes with RNA polymerase II on chromatin. Recruited to actively transcribed loci.
Domain	PF14826 FACT complex subunit SPT16 N-terminal lobe domain PF00557 Metallopeptidase family M24 PF08512 Histone chaperone Rttp106-like PF08644 FACT complex subunit (SPT16/CDC68)
Function	Component of the FACT complex, a general chromatin factor that acts to reorganize nucleosomes. The FACT complex is involved in multiple processes that require DNA as a template such as mRNA elongation, DNA replication and DNA repair. During transcription elongation the FACT complex acts as a histone chaperone that both destabilizes and restores nucleosomal structure. It facilitates the passage of RNA polymerase II and transcription by promoting the dissociation of one histone H2A-H2B dimer from the nucleosome, then subsequently promotes the reestablishment of the nucleosome following the passage of RNA polymerase II. The FACT complex is probably also involved in phosphorylation of 'Ser-392' of p53/TP53 via its association with CK2 (casein kinase II).

> Gene Ontology [ TOP ]
Biological Process	GO:0006260 DNA replication GO:0006333 chromatin assembly or disassembly GO:0006337 nucleosome disassembly GO:0006354 DNA-templated transcription, elongation GO:0006368 transcription elongation from RNA polymerase II promoter GO:0031498 chromatin disassembly GO:0032784 regulation of DNA-templated transcription, elongation GO:0032786 positive regulation of DNA-templated transcription, elongation GO:0032984 macromolecular complex disassembly GO:0032986 protein-DNA complex disassembly GO:0034728 nucleosome organization GO:0043241 protein complex disassembly GO:0071824 protein-DNA complex subunit organization GO:0072331 signal transduction by p53 class mediator GO:1901796 regulation of signal transduction by p53 class mediator
Molecular Function	-
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1643685: Disease R-HSA-112387: Elongation arrest and recovery R-HSA-167152: Formation of HIV elongation complex in the absence of HIV Tat R-HSA-167200: Formation of HIV-1 elongation complex containing HIV-1 Tat R-HSA-112382: Formation of RNA Pol II elongation complex R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-162906: HIV Infection R-HSA-162587: HIV Life Cycle R-HSA-167169: HIV Transcription Elongation R-HSA-167287: HIV elongation arrest and recovery R-HSA-5663205: Infectious disease R-HSA-162599: Late Phase of HIV Life Cycle R-HSA-167290: Pausing and recovery of HIV elongation R-HSA-167238: Pausing and recovery of Tat-mediated HIV elongation R-HSA-674695: RNA Polymerase II Pre-transcription Events R-HSA-73857: RNA Polymerase II Transcription R-HSA-75955: RNA Polymerase II Transcription Elongation R-HSA-5633007: Regulation of TP53 Activity R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation R-HSA-6796648: TP53 Regulates Transcription of DNA Repair Genes R-HSA-167243: Tat-mediated HIV elongation arrest and recovery R-HSA-167246: Tat-mediated elongation of the HIV-1 transcript R-HSA-167172: Transcription of the HIV genome R-HSA-3700989: Transcriptional Regulation by TP53

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-1643685: Disease
R-HSA-112387: Elongation arrest and recovery
R-HSA-167152: Formation of HIV elongation complex in the absence of HIV Tat
R-HSA-167200: Formation of HIV-1 elongation complex containing HIV-1 Tat
R-HSA-112382: Formation of RNA Pol II elongation complex
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-167169: HIV Transcription Elongation
R-HSA-167287: HIV elongation arrest and recovery
R-HSA-5663205: Infectious disease
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-167290: Pausing and recovery of HIV elongation
R-HSA-167238: Pausing and recovery of Tat-mediated HIV elongation
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75955: RNA Polymerase II Transcription Elongation
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation
R-HSA-6796648: TP53 Regulates Transcription of DNA Repair Genes
R-HSA-167243: Tat-mediated HIV elongation arrest and recovery
R-HSA-167246: Tat-mediated elongation of the HIV-1 transcript
R-HSA-167172: Transcription of the HIV genome
R-HSA-3700989: Transcriptional Regulation by TP53

Summary
Symbol	SUPT16H
Name	SPT16 homolog, facilitates chromatin remodeling subunit
Aliases	FACTP140; SPT16/CDC68; FLJ14010; FLJ10857; CDC68; facilitates chromatin remodeling 140 kDa subunit; suppress ......
Chromosomal Location	14q11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SUPT16H and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SUPT16H
Name	SPT16 homolog, facilitates chromatin remodeling subunit
Aliases	FACTP140; SPT16/CDC68; FLJ14010; FLJ10857; CDC68; facilitates chromatin remodeling 140 kDa subunit; suppress ......
Chromosomal Location	14q11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SUPT16H in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SUPT16H
Name	SPT16 homolog, facilitates chromatin remodeling subunit
Aliases	FACTP140; SPT16/CDC68; FLJ14010; FLJ10857; CDC68; facilitates chromatin remodeling 140 kDa subunit; suppress ......
Chromosomal Location	14q11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SUPT16H in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.12	0.603
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.518	0.816
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.178	0.918
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.203	0.338
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.265	0.909
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.126	0.966
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.162	0.714
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.039	0.985
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.329	0.885
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.207	0.897
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.684	0.775
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.109	0.0735

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SUPT16H in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	1.4	13.4	0.0181
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	1.7	13.1	0.032
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SUPT16H
Name	SPT16 homolog, facilitates chromatin remodeling subunit
Aliases	FACTP140; SPT16/CDC68; FLJ14010; FLJ10857; CDC68; facilitates chromatin remodeling 140 kDa subunit; suppress ......
Chromosomal Location	14q11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SUPT16H. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SUPT16H
Name	SPT16 homolog, facilitates chromatin remodeling subunit
Aliases	FACTP140; SPT16/CDC68; FLJ14010; FLJ10857; CDC68; facilitates chromatin remodeling 140 kDa subunit; suppress ......
Chromosomal Location	14q11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SUPT16H. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SUPT16H. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SUPT16H
Name	SPT16 homolog, facilitates chromatin remodeling subunit
Aliases	FACTP140; SPT16/CDC68; FLJ14010; FLJ10857; CDC68; facilitates chromatin remodeling 140 kDa subunit; suppress ......
Chromosomal Location	14q11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SUPT16H. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SUPT16H
Name	SPT16 homolog, facilitates chromatin remodeling subunit
Aliases	FACTP140; SPT16/CDC68; FLJ14010; FLJ10857; CDC68; facilitates chromatin remodeling 140 kDa subunit; suppress ......
Chromosomal Location	14q11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SUPT16H expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SUPT16H
Name	SPT16 homolog, facilitates chromatin remodeling subunit
Aliases	FACTP140; SPT16/CDC68; FLJ14010; FLJ10857; CDC68; facilitates chromatin remodeling 140 kDa subunit; suppress ......
Chromosomal Location	14q11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SUPT16H and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SUPT16H
Name	SPT16 homolog, facilitates chromatin remodeling subunit
Aliases	FACTP140; SPT16/CDC68; FLJ14010; FLJ10857; CDC68; facilitates chromatin remodeling 140 kDa subunit; suppress ......
Chromosomal Location	14q11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SUPT16H collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SUPT16H